Eli Lilly, Clenching Its Fist
Update time:
2026-08-14 11:15
Reads:
A Trillion-Dollar Pharma Giant Decides to Launch a New Sweep.
On August 12, Eli Lilly filed lawsuits simultaneously in federal courts in California and Texas, naming six U.S. companies as defendants.
Some of them call themselves "medical spas," others market themselves as "wellness clinics," and still others are active online as "peptide suppliers." Lilly accuses these entities of illegally selling a drug that has not yet been approved anywhere in the world — retatrutide.
How powerful is this drug?
In May this year, Lilly announced top-line results from a pivotal Phase III trial: over 80 weeks of treatment, participants receiving the highest dose of 12 mg achieved an average weight loss of 28.3% — nearly one-third of participants lost at least 30% of their body weight. These numbers were previously seen only with bariatric surgery.
For this reason, it is referred to by black-market buyers on social media as "reta," "r3ta," and even playfully as "ratatouille."
But that is precisely where the problem lies. An unapproved drug still in Phase III clinical trials is already being peddled across more than 14,000 websites, advertisements, and social media posts in over 100 countries worldwide.
U.S. Customs and Border Protection data is alarming. In fiscal year 2025, over 690 shipments of illegal GLP-1 drugs were seized; in July 2026 alone, seizures surged to over 1,400 shipments.
Max Denning, Lilly's global patient safety vice president for cardiometabolic health, said tracking these counterfeits is like playing a game of "whack-a-mole." "This is a huge problem, a global problem," he said. "It's not something we can solve on our own."
So Lilly moved beyond warnings. It took six companies to court.
Chapter 1: Aiming at the Black Market
The lawsuit is not large in scale — six companies, two states. But its symbolic significance far exceeds the case itself.
Among the six defendants, Aesthetic Envy Cosmetic Centers is based in California; the other five — Astra LLC, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide Co. — are all in Texas.
They cover three business models: compounding pharmacies, medical spas, and online sellers. In other words, Lilly has essentially sued every channel through which the black market can reach consumers.
These defendants' marketing tactics are relatively "clever": they label their products as "for research-use only," attempting to exploit a loophole in federal regulations that allows the sale of "experimental-use-only" compounds. However, Lilly's complaint states that these companies actually sell directly to consumers, complete with detailed dosing instructions. One defendant even provides a calculator to help consumers figure out how much to inject — something that should be done by a licensed physician.
Lilly's Chief Medical Officer David Hyman said in a statement: "What is being sold on the black market is not medicine at all — it is completely unverified and unapproved, and not worth the risk."
The lawsuits are just the tip of the iceberg. Lilly revealed that it has referred more than 200 entities to the FDA, the U.S. Department of Justice, state attorneys general, law enforcement agencies, and professional licensing boards. In more than 100 countries, Lilly has reported over 14,000 websites, advertisements, social media posts, and product listings. The company is also coordinating with law enforcement in the UK, Brazil, New Zealand, Saudi Arabia, and Hong Kong.
The FDA has also been active. Since 2024, the FDA has issued warning letters to at least 16 companies claiming to sell retatrutide. The FDA has made it clear that pharmacies compounding retatrutide are violating the law, and that so-called "for research-use only" products are "of unknown quality and may pose health risks." However, according to an August 11 analysis by Bloomberg, many of these companies continued selling counterfeit versions even after receiving warning letters.
Even more concerning is the quality of these counterfeits. Lab analyses have revealed issues ranging from inaccurate dosing — from zero to excessive amounts — to completely incorrect active ingredients (such as insulin contamination). Many products are manufactured under non-sterile conditions and may be contaminated with microorganisms. Since January 2026, at least six cases of acute hepatotoxicity have been reported in patients who injected products labeled as retatrutide.
Lilly has also called on social media platforms, e-commerce companies, payment processors, credit card companies, and logistics providers to cut off the infrastructure supporting illegal transactions.
This is not Lilly's first lawsuit of this kind. In 2023, the company sued eight companies that were manufacturing or selling compounded versions of Mounjaro; in April 2025, it sued four telehealth companies selling counterfeit versions of Zepbound and Mounjaro. But retatrutide has taken this battle to an entirely new level.
Chapter 2: Why Retatrutide?
To understand why Lilly is so concerned, one must first understand what retatrutide is and why it has driven the black market into a frenzy.
Retatrutide is a GCG/GIP/GLP-1 triple receptor agonist — it targets three hormone receptors simultaneously. The already-approved semaglutide (Novo Nordisk's Ozempic/Wegovy) is a GLP-1 single-target drug; tirzepatide (Lilly's Mounjaro/Zepbound) is a GLP-1/GIP dual-target drug. Retatrutide is the first triple-target drug to enter Phase III clinical trials.
In May, Lilly announced top-line results from the TRIUMPH-1 Phase III trial. The data was stunning: the 12 mg dose group achieved an average weight loss of 70.3 pounds (28.3%) over 80 weeks, with 45.3% of participants achieving weight loss of 30% or more. In a pre-specified extension study, participants who continued treatment to 104 weeks achieved an average weight loss of 85 pounds (30.3%).
In July, Lilly announced positive results from TRIUMPH-2 and TRIUMPH-3: up to 20.8% weight loss in obese patients with type 2 diabetes, and up to 22.6% in severely obese patients with cardiovascular disease.
One analyst described the efficacy as "surgery-level." The headline of a Pulse Today article read: "New weight-loss injections are as effective as bariatric surgery."
It is precisely this "surgery-comparable" efficacy that has ignited global consumer desire and fueled the black market frenzy.
Since Lilly released interim study results in 2023, suggesting that this drug could be more potent than any weight-loss drug on the market, people around the world have been trying to get their hands on black-market versions.
They buy from overseas sellers who label products as "for research-use only" to circumvent regulations. On social media, buyers have invented code names — "reta," "r3ta," "ratatouille" — to bypass platform restrictions on weight-loss content.
An analysis by the non-profit Partnership for Safe Medicines of FDA data shows that approximately 6.8 kilograms of retatrutide — equivalent to hundreds of thousands of doses — entered the U.S. between January and April 2026. The New York Times reported that as many as hundreds of thousands of doses of retatrutide may have entered the U.S. in the first four months of 2026 alone.
Industry estimates place the overall peptide black market at between $1 billion and $3 billion.
Even more striking is law enforcement data. U.S. Customs and Border Protection seized over 690 shipments — more than 31,000 units — of illegal GLP-1 drugs in fiscal year 2025; in July 2026 alone, seizures exceeded 1,400 shipments totaling nearly 90,000 vials. Customs officers in Cincinnati intercepted over 5,000 shipments of peptide products between December 2025 and March 2026.
For Lilly, the black market is not just a business problem, but a safety concern. Retatrutide is still in large-scale clinical trials, and any safety issue caused by counterfeits — even if unrelated to the genuine product — could damage the drug's reputation. And this drug carries Lilly's most important growth expectations for the next decade.
Chapter 3: A Hundred-Billion-Dollar Bet
How high are Lilly's expectations for retatrutide?
If approved, analysts project that retatrutide could generate over $5.4 billion in annual sales for Lilly by 2030. RBC Capital's model is more conservative, projecting $4.9 billion in 2030 sales; GlobalData's projection is even higher at $15.5 billion in 2031 sales. TD Cowen analysts gave a $3.8 billion 2030 forecast in January.
Whichever number is more accurate, this is a "blockbuster" drug.
Lilly itself is experiencing epic growth. In the second quarter of 2026, revenue grew 48% year-over-year to $23 billion, with adjusted earnings per share up 33%. Management raised full-year revenue guidance to $85–87 billion. The company's market capitalization remains around $1.1 trillion.
But behind the growth lie concerns. Realized prices declined approximately 13% year-over-year during the period, with U.S. market prices down about 9%. $2.78 billion in R&D expenses from multiple acquisitions pushed up the effective tax rate. The market's reaction to the stock price has not fully reflected the rapid revenue expansion.
Against this backdrop, retatrutide's success is critical. It is not only Lilly's next-generation flagship product in the weight-loss space, but also a key asset for maintaining its trillion-dollar market capitalization story.
However, the black market is threatening all of this.
Lilly faces a twofold dilemma. On one hand, counterfeit products on the black market could cause real safety incidents — if someone experiences serious adverse reactions after injecting "retatrutide" adulterated with insulin or with grossly inaccurate dosing, public panic could spill over to the genuine product. On the other hand, the proliferation of the black market is eroding Lilly's future pricing power and market order. When a drug is already being "illegally used" by hundreds of thousands of people while still in clinical trials, by the time it is officially launched, the market has already been severely compromised.
Lilly Vice President Denning called it an "urgent public health crisis." This is not alarmist. An FDA spokesperson has urged consumers "not to use retatrutide unless they are part of a clinical trial." But consumer desire — and black-market sellers' greed — clearly overrides these warnings.
Lilly has already taken a series of measures. Beyond lawsuits and reports, the company is urging regulators and law enforcement to prioritize enforcement actions "and coordinate across borders to dismantle criminal networks involved in selling retatrutide." Federal and local authorities have taken some "encouraging" actions, including large-scale seizures by Cincinnati customs and criminal sentences against peptide company owners.
But Denning also admits it is like "whack-a-mole" — knock one down and another pops up. As long as demand exists, the black market will not disappear.
Chapter 4: Countdown to 2027
In July, Lilly revealed plans to submit a Biologics License Application (BLA) for retatrutide to the FDA in the first quarter of 2027.
This timeline is later than the market had previously expected. Lilly had previously indicated that it could submit an application as early as 2026. But given the scale of retatrutide's Phase III clinical program — 14 of 20 clinical trials are Phase III, with over 70% of trials completed or fully enrolled — the Q1 2027 timeline remains quite aggressive.
Retatrutide's indications are also expanding. Beyond obesity and type 2 diabetes, Lilly is preparing to submit materials for the drug's use in treating obstructive sleep apnea and knee osteoarthritis pain.
In Phase III trials, retatrutide reduced the severity of moderate-to-severe obstructive sleep apnea by 60.6% and reduced knee osteoarthritis pain by up to 73.1%. These data suggest retatrutide's market potential extends far beyond a simple weight-loss drug.
If all goes well, retatrutide will officially launch between the second half of 2027 and early 2028. At that point, it will compete head-on with Novo Nordisk's next-generation products for a share of the global weight-loss market, worth hundreds of billions of dollars.
But before that, Lilly still has one problem it must solve: the black market.
From 2024 to now, the FDA has issued at least 16 warning letters. Lilly has reported more than 200 entities and over 14,000 online listings. The volume of illegal goods seized by Customs in July 2026 alone exceeded the full-year total for 2025. One peptide company owner was sentenced to six years in prison.
Unfortunately, these efforts still do not appear to have curbed the black market's spread.
Lilly is well aware that lawsuits and reports alone are far from enough. The company is calling for a multi-stakeholder governance system: regulators must prioritize enforcement and coordinate across borders; social media and e-commerce platforms must proactively stop illegal activities; credit card companies, payment processors, and logistics providers must cut off infrastructure. This is a war that requires participation from the entire value chain.
When a drug with "surgery-level" efficacy is still in clinical trials and already hundreds of thousands of people are injecting counterfeit versions on the black market, this pharma giant faces not just a business defense battle, but a public health offensive. The outcome of this war will directly affect the health and safety of tens of millions of patients — and directly impact Lilly's trillion-dollar market capitalization future.
2027 is approaching. The countdown to retatrutide's launch has begun. But before that, Lilly must first win this game of whack-a-mole.
Related News